Sandoz

Sandoz prepares early 2019 launch for EpiPen alternative Symjepi at 16% discount
Sandoz prepares early 2019 launch for EpiPen alternative Symjepi at 16% discount
Fierce Pharma
Novartis
Sandoz
generics
Symjepi
EpiPens
Teva Pharmaceutical
Mylan
Flag link:
Pear, Sandoz launch first FDA-approved digital therapeutic
Pear, Sandoz launch first FDA-approved digital therapeutic
BioCentury
Pear Therapeutics
Sandoz
digital therapeutics
substance abuse
reSET
Flag link:
Novartis 'completely committed' to Sandoz, has no split-off plan
Novartis 'completely committed' to Sandoz, has no split-off plan
Yahoo/Reuters
Novartis
Sandoz
generics
Flag link:
Novartis' Sandoz calls it quits on Rituxan biosimilar after FDA requests more data
Novartis' Sandoz calls it quits on Rituxan biosimilar after FDA requests more data
Fierce Pharma
Novartis
Sandoz
FDA
biosimilars
Roche
Rituxan
Flag link:
Novartis abandons effort for U.S. approval of biosimilar rituximab
Novartis abandons effort for U.S. approval of biosimilar rituximab
Yahoo/Reuters
Novartis
Sandoz
rituximab
biosimilars
Roche
Flag link:
Battle Over Humira Begins in Europe as 5-Year Wait Begins in US
Battle Over Humira Begins in Europe as 5-Year Wait Begins in US
RAPS.org
Europe
AbbVie
Humira
Amgen
Samsung Bioepis
Mylan Labs
Novartis
Sandoz
Fresenius Kabi
Boehringer Ingelheim
Flag link:
Sandoz free to launch Humira biosimilar in Europe following AbbVie deal
Sandoz free to launch Humira biosimilar in Europe following AbbVie deal
Pharmaforum
Novartis
Sandoz
AbbVie
Humira
biosimilars
Europe
Flag link:
Amgen, Sandoz begin biosimilar trial with top-selling Enbrel at stake
Amgen, Sandoz begin biosimilar trial with top-selling Enbrel at stake
Biopharma Dive
Amgen
Sandoz
Enbrel
biosimilars
Novartis
Flag link:
Novartis sells parts of Sandoz for $1bn
Novartis sells parts of Sandoz for $1bn
Pharmaforum
Novartis
Sandoz
M&A
dermatology
Aurobindo
Flag link:
Omeros Prevails in Patent Dispute With Sandoz
Omeros Prevails in Patent Dispute With Sandoz
CP Wire
Omeros
Sandoz
Novartis
patents
Omidria
Flag link:
Omeros Prevails in Patent Dispute With Sandoz
Omeros
Omidria
Sandoz
lawsuits
patent lawsuits
Flag link:
Novartis steps in to compete with Mylan’s Epipen
Novartis steps in to compete with Mylan’s Epipen
Drug Delivery Business News
Adamis Pharmaceuticals
Novartis
Sandoz
Symjepi
Mylan
EpiPens
Flag link:
Novartis receives EU approval for biosimilar Zessly
Novartis receives EU approval for biosimilar Zessly
Reuters
Novartis
Sandoz
biosimilars
Europe
Zessly
Flag link:
Aurobindo bids $1.6B for Novartis' U.S. dermatology generics: report
Aurobindo bids $1.6B for Novartis' U.S. dermatology generics: report
Fierce Pharma
Aurobindo
Novartis
Sandoz
M&A
dermatology
India
Flag link:
Impax Laboratories Agrees to Settle Antitrust Lawsuit
Impax Laboratories Agrees to Settle Antitrust Lawsuit
CP Wire
Impax Laboratories
Solodyn
antitrust
Medicis
Lupin
Sandoz
Flag link:
No more Mr Nice Guy: GlaxoSmithKline is coming out of its corner swinging
No more Mr Nice Guy: GlaxoSmithKline is coming out of its corner swinging
Endpoints
GSK
R&D
Pharma CEOs
Emma Walmsley
Advair
Novartis
Sandoz
Gilead Sciences
HIV
Flag link:
FDA rejects Novartis’ Advair generic, leaving GSK without rival
FDA rejects Novartis’ Advair generic, leaving GSK without rival
Drug Delivery Business News
FDA
Novartis
Advair
generics
GSK
Sandoz
Flag link:
Novartis aims for US approval of Humira biosimilar
Novartis aims for US approval of Humira biosimilar
Biopharma Dive
Novartis
Humira
biosimilars
AbbVie
Sandoz
Flag link:
Allergan says court affirms patent loss to Sandoz on eye drug
Allergan says court affirms patent loss to Sandoz on eye drug
Reuters
Allergan
patents
Sandoz
generics
Combigan
Flag link:
Novartis seeks to revive Neulasta biosim prospects with data showing it matches Amgen’s blockbuster
Novartis seeks to revive Neulasta biosim prospects with data showing it matches Amgen’s blockbuster
Fierce Pharma
Novartis
Neulasta
biosimilars
Amgen
Sandoz
FDA
Flag link:

Pages